D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed.

Participants will be randomly assigned to one of four groups:

• Group 1 participants will continue to take d4T as part of their antiretroviral (ARV) regimen, and will be given the vitamin supplements

• Group 2 will continue to take d4T without vitamin supplements

• Group 3 will switch from d4T to abacavir and receive the vitamins

• Group 4 will switch from d4T to abacavir without vitamin supplements.

The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Collaborators: CIHR Canadian HIV Trials Network; GlaxoSmithKline
• Treatments: Abacavir; Riboflavin; Thiamine

Criteria

Inclusion Criteria:

• Be HIV-positive

• Be 18 years of age or older

• Have a viral load equal to or below 50 copies/mL

• Have been on a d4T-containing multiple drug regimen (at least three agents in total) for at least six months

• Have been on a stable ARV regimen for the three months prior to enrollment

• Have a venous lactic acid measurement above 2.1 mmol/L within the three months prior to enrollment and two consecutive measurements above 2.1 but lower than 6.0 within a two-week period of screening

• Be willing to discontinue L-carnitine and/or coenzyme Q10

• Be willing and able to provide informed consent

Exclusion Criteria:

• Pregnancy or breastfeeding

• Venous lactic acid equal to or above 6.0 mmol/L

• Previous exposure to abacavir

• Virologic rebound while on a previous regimen consisting of dual or triple nucleoside reverse transcriptase inhibitors (NRTIs)

• Use of hydroxyurea within the three months prior to enrollment

• Use of metformin

• Any acute cardiopulmonary illness or infection

• New AIDS-defining illness diagnosed within four weeks of enrollment

• Riboflavin or thiamine supplementation above 20 mg/day within 30 days prior to enrollment